Ginkgo Bioworks Holdings (DNA) Payables (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Payables data on file, last reported at $16.3 million in Q1 2026.

• Quarterly Payables rose 44.75% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 44.75% YoY) and the FY2025 annual result came in at $10.6 million, down 25.43% from the prior year.
• Payables grew to $16.3 million in Q1 2026, from $10.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $35.3 million in Q1 2022 to a low of $9.3 million in Q4 2023.
• A 5-year average of $16.0 million and a median of $13.6 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables surged 2379.71% — and 2025, when it plunged 58.26%.
• Tracing DNA's Payables over 5 years: stood at $10.5 million in 2022, then dropped by 10.79% to $9.3 million in 2023, then soared by 51.98% to $14.2 million in 2024, then fell by 25.43% to $10.6 million in 2025, then surged by 54.35% to $16.3 million in 2026.
• The last three Payables figures came in at $16.3 million (Q1 2026), $10.6 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.